Progestins/Antiprogestins: Role in Pathogenesis and Treatment for
Gynecology & Obstetrics

Gynecology & Obstetrics
Open Access

ISSN: 2161-0932

Editorial - (2012) Volume 2, Issue 3

Progestins/Antiprogestins: Role in Pathogenesis and Treatment for Endometriosis

Shylesh S. Bhaskaran and Hareesh B. Nair*
Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio TX 78227, USA
*Corresponding Author: Hareesh B. Nair, Southwest National Primate Research Center, Texas Biomedical Research Institute, 7620 NW Loop 410, San Antonio TX 78227, USA, Tel: 210-258-9515, Fax: 210-258-9883 Email:


Endometriosis is a painful gynecological condition in the fertile-age in which presence of endometrial tissue develops outside the uterus, which under normal situation found only in the inside lining of the uterus, attach to pelvic floor, endometrium or peritoneal cavity. Endometriosis cause abdominal pain, bleeding, irregular menstrual cycles with excessive pain, inflammatory responses and infertility. Retrogressive menstruation and invasion theories have been well studied in the pathogenesis of endometriosis. Role of steroids including estrogen, gonadotropin releasing hormones has been documented and major treatment strategies are based on steroid biology of endometriosis. Current treatment strategies are less successful and solely focusing on the late phase of the disease. The exact role of progesterone in the initiation (initial phase) of endometriosis has not been well studied or overshadowed by the concept of progesterone resistance that occurs in late phase in endometriosis. In this review, we are discussing the role of progesterone and potential use of anitprogestins or possible combination treatment strategies which may help to combat initiation and progression of endometriosis.

Keywords: Endometriosis; Progesterone; Antiprogestins; Focal adhesion kinase (FAK); Personalized therapy

Endometriosis is a benign gynecological disease that affects about 10% of reproductive age women associated with pelvic pain and remains as a notable reason for infertility [1]. Patients with endometriosis also show reduced rates of follicular growth, reduced functional ability of the pre-ovulatory follicle, reduced fertilization rates, irregular preimplantation embryonic development, altered early luteal function and reduced implantation rates [2,3]. Classical treatments include progestins and antiestrogens and GNRH antagonists, often lead to undesirable side effects and compromising quality of life [4]. Endometriosis is expensive to treat and complex to study because there are notable delays in the diagnosis and variations in symptoms and disease development in patients [5]. Also, at the time of clinical presentation, most women have established disease, making the initiation of endometriosis is difficult to study. The implantation hypothesis of retrograde menstruation by Sampson [6] is the most widely accepted theory of endometriosis. Although retrograde menstruation occurs in all women, the reason for adhesion and invasion of endometriotic epithelial and stromal cells on peritoneal mesothelium in only 10% of women remain elusive.

Only sparse reports are available regarding the molecular signalling of endometrial pathogenesis leading to the initiation and progression of endometriosis. A Large body of scientific evidence suggests that estrogen and Estrogen Receptors (ERs) are involved in progression of endometriosis [7]. Although progestins are used to treat endometriosis, the exact role of progesterone in the formation (initiation) of endometriotic lesions is poorly understood. The main side effects of progestin therapies are interim bleeding, weight gain and reduced libido. Oral contraceptives are generally well tolerated but they are not as effective in reducing pain [8]. GnRH-antagonists are highly effective but they lead to a significant reduction in bone density [9]. Progesterone is produced by the corpus luteum to maintain early pregnancy. Low progesterone secretion in the luteal phase has been associated with habitual abortion. Hence it is logical to hypothesize that antiprogestins given in early pregnancy can act as abortifaciants and could provide alternative to surgical abortion.

Based on our laboratory experiments, progression of endometriosis were primarily depends on the levels of progesterone secretion by the corpus luteum at the time of attachment of menstrual endometrial epithelial/stromal cells to peritoneal mesothelium. Progesterone level is maintained high enough to support the attachment, subsequent invasion and then dramatically drops after 1-2 weeks. This window period is very crucial for progesterone induced proliferation and activation of progesterone target genes to ease the cellular invasion of the attached menstrual endometrial or stromal cells. Hence we point out that endometriosis is a pseudo-pregnancy state and the corpus luteum produces progesterone to support and maintain the attached endometrial/stromal cells as if it were a fertilized egg. In most clinical cases at the time of diagnosis (2-6 months), the circulating as well as tissue levels of progesterone are too low to be detected and often misunderstood as progesterone resistance [10,11].

Another important aspect in the context of the ideal profile of an antiprogestin for endometriosis is its effect on the endometrium [12]. The endometrium is under a well balanced control of estrogens and progestins. Estrogens lead to a strong proliferation of the endometrium that might lead to endometrial hyperplasia if this effect is not controlled through the antiestrogenic effect of progestins. Sustained, persistent estrogenic stimulation in the absence of progestin ultimately results in hyperplasia. Our results pointing the fact that effect of estrogen is apparent only in the second phase of the disease (unpublished data), since the first wave of progesterone secretion by the corpus luteum to support the pseudo egg is sufficient to initiate the menstrual endometrial/stromal cell attachment on the peritoneal mesothelium. The treatment with a pure antiprogestin may therefore inhibit menstrual endometrial/stromal cell attachment on peritoneal mesothelium and also may inhibit the subsequent second wave of estrogen induced proliferation.

Currently, RU 486 (Mifepristone) is the first and most widely studied antiprogestin. At the present time, it has been approved only for termination of second trimester pregnancies [13]. The long term application of Mifepristone is hampered due to its strong antiglucocorticoid effect [14]. Newer antiprogestins, CDB 4124, also known as Proellex®, was found to be 2.8 fold more potent than RU 486 without exhibiting any agonistic activity. The antiglucocorticoid activity was determined to be around 1/3 of that of Mifepristone [15]. The phase II clinical study evaluating the safety and efficacy of the selective progesterone receptor modulator Proellex® (CDB-4124) in the treatment of premenopausal women with symptomatic endometriosisextension study was discontinued due to adverse events (Clinical trials. gov; NCT00958412). There is unmet need for a better understanding of the role of progesterone in the initiation and progression of endometriosis that will expand our knowledge to develop better antiprogestins for the safer treatment of endometriosis with minimal or no anti-glucocorticoid side effects.


  1. Eskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24: 235-258.
  2. Tummon IS, Maclin VM, Radwanska E, Binor Z, Dmowski WP (1988) Occult ovulatory dysfunction in women with minimal endometriosis or unexplained infertility. Fertil Steril 50: 716-720.
  3. Stilley JA, Woods-Marshall R, Sutovsky M, Sutovsky P, Sharpe-Timms KL (2009) Reduced fecundity in female rats with surgically induced endometriosis and in their daughters: a potential role for tissue inhibitors of metalloproteinase 1. Biol Reprod 80: 649-656.
  4. Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, et al. (2011) Ovarian Cancer Association Consortium; Australian Cancer Study (Ovarian Cancer) (ACS); Australian Ovarian Cancer Study Group (AOCS). Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertil Steril 95: 40-45.
  5. Matsuzaki S, Canis M, Pouly JL, Rabischong B, Botchorishvili R, et al. (2006) Relationship between delay of surgical diagnosis and severity of disease in patients with symptomatic deep infiltrating endometriosis. Fertil Steril 86: 1314-1316.
  6. Sampson JA (1927) Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. Am J Pathol 3: 93-110.
  7. Vercellini P, Cortesi I, Crosignani PG (1997) Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 68: 393-401.
  8. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, et al. (1993) A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 60: 75-79.
  9. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, et al. (2006) Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol 248: 94-103.
  10. Hirota Y, Cha J, Dey SK (2010) Revisiting reproduction: Prematurity and the puzzle of progesterone resistance. Nat Med 16: 529-531.
  11. Guttinger A, Critchley HO (2007) Endometrial effects of intrauterine levonorgestrel. Contraception 75: S93-S98.
  12. Gottlieb C, Bygdeman M (1991) The use of antiprogestin (RU 486) for termination of second trimester pregnancy. Acta Obstet Gynecol Scand 70: 199-203.
  13. Gaillard RC, Poffet D, Riondel AM, Saurat JH (1985) RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 61: 1009-1011.
  14. Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc. US Application Publication.
Citation: Bhaskaran SS, Nair HB (2012) Progestins/Antiprogestins: Role in Pathogenesis and Treatment for Endometriosis. Gynecol Obstet 2:e105.

Copyright: © 2012 Bhaskaran SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.